Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can age predict bladder cancer treatment success?

NCT ID NCT07798479

Knowledge-focused Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

Researchers are investigating whether a patient's age influences the outcomes of BCG therapy for a high-risk form of bladder cancer called pT1 high-grade. This study reviews medical records from 64 patients who received standard BCG treatment after tumor removal. The goal is to compare cancer recurrence, progression, and survival between younger and older patients. The findings could help doctors decide if age should factor into treatment recommendations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bacillus Calmette-Guérin (BCG) therapy, given directly into the bladder as standard care
What this could lead to
If age does not affect outcomes, older patients may continue to receive BCG treatment, helping to personalize bladder cancer care.
What could go wrong
This is a small, retrospective study, so results may not apply to all patients. Other factors like overall health and tumor traits also matter.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

64 people

The number who actually took part.

Started

Mar 2009

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of patients with primary pT1 high-grade urothelial bladder cancer who underwent transurethral resection of the bladder tumor, followed by repeat resection confirming no residual tumor, and subsequently received intravesical BCG therapy according to current EAU guidelines. The retrospective multicenter cohort includes 64 patients. Patients are evaluated according to age, with comparisons using age thresholds of 70 and 75 years. The study population includes both male and female patients and represents patients treated with standard-of-care BCG therapy in routine clinical practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Treatment: TUR-B + Re-TUR-B + BCG (≥6 instillations) Exclusion Criteria: * Re-TUR-B \> 56 after TUR-B * Residual tumor on re-TUR-B histology * non-urothelial histology

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms Recurrence urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer NMIBC

More trials for these conditions

Other studies related to the condition(s) this trial covers.